Info

Exocell, Inc. is a biopharmaceutical company focused on the diagnosis and treatment of complications due to diabetes. Currently, Exocell markets reagents for diabetes research and has a compound in Phase III clinical trials (Exo 226) for the prevention and treatment of kidney disease due to diabetes. Exocell has discovered one mechanism that leads to kidney failure. The mechanism is triggered by the increased presence and binding of glycosylated proteins to a receptor for these glycosylated proteins. This binding leads to fibrosis of the kidney and ultimately renal failure.